medigraphic.com

2007, Number 1

<< Back Next >>

Rev Mex Anest 2007; 30 (1)

Effects of pharmacologically-induced anxiety on nociception

Jiménez-Velázquez G, Fernández-Guasti A, López-Muñoz FJ

Language: Spanish
References: 34
Page: 14-19
PDF size: 95.17 Kb.


ABSTRACT

Preclinical and clinical studies have reported relationships between anxiety and nociception. Clinical data have shown that the perception of pain increases under stress, whereas studies in animals revealed that diverse environmental stimuli that generate anxiety-like behaviors induce antinociception. This study was conducted to investigate the potential influence of pharmacologically induced-anxiety on nociception by using a model of inflammatory pain (PIFIR model). To induce experimental anxiety, yohimbine was administered to rats and its effect was measured through the rat burying behavior test. Nociception was induced by an intra-articular injection of 15% uric acid into the knee joint of the right hind limb. Yohimbine (0.5, 1.0 and 2.0 mg/kg, i.p.) was administered 15 min before the uric acid and the ability of the rat to use the injured hind limb was recorded. The burying behavior test showed that yohimbine caused a dose-dependent increase in the cumulative time of burying, which in turns indicates an increase in anxiety. Yohimbine, administered alone, was unable to produce nociception in the PIFIR model but effectively prevented the nociceptive actions of uric acid. The results showed an influence of anxiety on nociception since increased-anxiety (by yohimbine) prevented nociception. This study shows an interesting interaction between anxiety and nociception.


REFERENCES

  1. Ploghaus A, Narain C, Beckmann CF, Clare S, Banticks S, Wise R, Matthews PM, Rawlins JNP, Tracey I. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 2001;21:9896-9903.

  2. Schanberg LE, Sandstrom MJ, Starr K, Gil KM, Lefebvre JC, Keefe FJ, Affleck G, Tennen H. The relationship of daily mood and stressful events to symptoms in juvenile rheumatic disease. Arthritis Care & Res 2000;13:33-41.

  3. Hadjistavropoulos HD, Asmundson GJG, Kowalyk KM. Measures of anxiety: is there a difference in their ability to predict functioning at three-month follow-up among pain patient? Eur J Pain 2003:1-11.

  4. Das DA, Grimmer KA, Sparnon AL, Mcrae SE, Thomas BH. The efficacy of playing a virtual reality game in modulating pain for children with acute burn injuries: A randomized controlled trial. BMC Pediatric 2005;5:1-10.

  5. Meagher MW, Arnau RC, Rhudy JL. Pain and emotion: effects of affective picture modulation. Psychos Med 2001;63:79-90.

  6. Marchand S, Arsenault P. Odors modulate pain perception: a gender-specific effect. Physiol Behav 2002;76:251-256.

  7. Villemure C, Slotnick BM, Bushnell MC. Effects of odors on pain perception: deciphering the roles of emotion and attention. Pain 2003;106:101-108.

  8. Cornwall A, Donderi DC. The effect of experimentally induced anxiety on the experience of pressure pain. Pain 1988;35:105-113.

  9. Jones A, Zacharie R, Arendt-Nielsen L. Dispositional anxiety and experience of pain: gender-specific effects. Eur J Pain 2003;7:387-395.

  10. Vickers ER, Boocock H. Chronic orofacial pain associated with psychological morbidity and negative personality changes: a comparison to the general population. Aust Dent J 2005;50:21-30.

  11. Christie W, Moore C. The impact of humor on patients with cancer. Clin Oncol Nurs 2005;9:211-218.

  12. Kavaliers M, Innes D. Male Scent-Induced Analgesia in the Deer Mouse, Peromyscus maniculatus: Involvement of Benzodiazepine Systems. Physiol & Behav 1988;42:131-135.

  13. Rodgers RJ, Randall JI. Benzodiazepines ligands, nociception and “defeat” analgesia in male mice. Psychopharmacol 1987 a;91:305-315.

  14. Helmstetter FJ. Stress-induced hypoalgesia and defensive freezing are attenuated by application of diazepam to the amygdala. Pharmacol Biochem Behav 1993;44:433-438.

  15. Rodgers RJ, Shepherd JK. 5-HT1A agonist, 8-hydroxy-2(DI-n-propylamino)tetralin (8-OH-DPAT), inhibits non-opioid analgesia in defeated mice: influence of route of administration. Psychopharmacol 1989;97:163-165.

  16. Teskey GC, Kavaliers M, Hirst M. Social conflict activates opioids analgesic and ingestive behaviors in male mice. Life Sc 1984;35:303-315.

  17. Rodgers RJ, Lee C, Shepherd JK. Effects of diazepam on behavioral and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacol 1992;106:102-110.

  18. Lee C, Rodgers RJ. Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacol 1990;102:507-513.

  19. Bellgowan PS, Helmstetter FJ. Neural systems for the expression of hypoalgesia during nonassociative fear. Behav Neurosci 1996;110:727-736.

  20. Nunes-De-Souza RL, Canto-De-Souza A. Da-Costa M, Fornari FG, Péla IR. Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology 2000;150:300-310.

  21. Tershner SA, Helmstetter FJ. Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res 2000;865:17-26.

  22. Vendruscolo LF, Pamplona FA, Takahashi RN. Strain and sex differences in the expression of nociceptive behavior and stress-induced analgesia in rats. Brain Res 2004;1033:277-283.

  23. Rodgers RJ, Randall JI. Are analgesic effects of social defeat mediated by Benzodiazepine Receptors? Physiol Behav 1987 b;41:279-289.

  24. López-Muñoz FJ, Castañeda-Hernández G, Villareal J, Salazar LA. A new model to assess analgesic activity: Pain-induced functional impairment in the rat (PIFIR). Drug Dev Res 1993;28:169-175.

  25. Covino BG, Dubner R, Gybels J, Kosterlitz HW, Liebeskind JC, Sternbach RA, Vyclicky L, Yamamura H, Zimmermann M. Ethical standards for investigations of experimental pain in animals. Pain 1980;9:141-143.

  26. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-110.

  27. Treit D. Animal models for study of anti-anxiety agents: A review. Neuroscienc Biobehavior Rev 1985;9:203-222.

  28. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and applications. 2nd Ed. Lea & Febiger: Philadelphia 1989.

  29. Uchihashi Y, Kamei M, Fukuda I, Nakai T, Karasawa F, Satoh T, Effects of alpha adrenoreceptor antagonists, prazosin and yohimbine, on intrathecal lidocaine-induced antinociception in mice. Acta Anaesthesiol Scand 2000;44:1083-1086.

  30. Dogrul A, Uzbay T. Topical clonidine antinociception. Pain 2004;111:385-391.

  31. Shannon HJ, Lutz EA. Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin (1A) receptors. Psychopharmacol 2000;149:93-97.

  32. Dessaint J, Yu W, Krause JE, Yue L. Yohimbine inhibits firing activities of rat dorsal root ganglion neurons by blocking Na+ channels and vanilloid VR1 receptor. Eur J Pharmacol 2004:11-20.

  33. Tanaka M, Yoshida M, Emoto H, Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 2000;405:397-406.

  34. Shah AA, Treit D. Infusion of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plus-maze and shock-probe burying tests. Brain Res 2004;996:31-40.




2020     |     www.medigraphic.com